A clinical webinar for GPs and mental health clinicians | Presented by The Psychedelic Consultancy
Many of your patients with chronic, treatment-resistant PTSD or depression may now be eligible for psychedelic-assisted therapy (PAT) under Australia's TGA Authorised Prescriber scheme. This webinar gives you the clinical knowledge and practical tools to assess suitability, navigate referral pathways, and support patients through the process.
We cover the evidence base for MDMA and psilocybin-assisted therapy, including an honest account of limitations and the current international regulatory landscape, how Australia's Authorised Prescriber scheme works, and a practical screening framework for identifying suitable candidates. We work through real case examples covering appropriate, borderline, and unsuitable referrals, and finish with an overview of training pathways for clinicians wanting to work within PAT teams, and what a good referral looks like in practice.
Learning outcomes
By the end of this session, you will be able to:
Describe the current evidence for PAT in treatment-resistant depression and PTSD, including its limitations
Explain Australia's Authorised Prescriber scheme and how patients currently access treatment
Apply appropriate inclusion and exclusion criteria when considering a referral
Navigate referral pathways to existing Authorised Prescribers and multidisciplinary services
Identify training pathways for clinicians wishing to work as PAT therapists
Presented by
Dr Joe Starke, Psychiatrist and Authorised Prescriber
Dr Sigi Gutjahr, Psychiatrist and Authorised Prescriber
Free access available for AP Compliance Program members: contact us for your code.